Found: 99
Select item for more details and to access through your institution.
Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL).
- Published in:
- 2019
- By:
- Publication type:
- case study
Communicating the diagnosis of a hematological neoplastic disease to patients' minor children: a multicenter prospective study.
- Published in:
- Oncologist, 2024, v. 29, n. 10, p. e1354, doi. 10.1093/oncolo/oyae104
- By:
- Publication type:
- Article
BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 8, p. 1632, doi. 10.1002/ajh.27359
- By:
- Publication type:
- Article
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. E296, doi. 10.1002/ajh.26618
- By:
- Publication type:
- Article
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. 1075, doi. 10.1002/ajh.26556
- By:
- Publication type:
- Article
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 12, p. E319, doi. 10.1002/ajh.25967
- By:
- Publication type:
- Article
Increased sFLT‐1/PlGF ratio in COVID‐19: A novel link to angiotensin II‐mediated endothelial dysfunction.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 8, p. E188, doi. 10.1002/ajh.25882
- By:
- Publication type:
- Article
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 1, p. 46, doi. 10.1002/ajh.25306
- By:
- Publication type:
- Article
Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 5, p. 607, doi. 10.1002/ajh.25043
- By:
- Publication type:
- Article
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 11, p. 1214, doi. 10.1002/ajh.24887
- By:
- Publication type:
- Article
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 10, p. E623, doi. 10.1002/ajh.24865
- By:
- Publication type:
- Article
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 12, p. 1206, doi. 10.1002/ajh.24536
- By:
- Publication type:
- Article
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 6, p. 606, doi. 10.1002/ajh.24360
- By:
- Publication type:
- Article
Chronic myeloid leukemia: Second-line drugs of choice.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 1, p. 67, doi. 10.1002/ajh.24247
- By:
- Publication type:
- Article
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 12, p. E227, doi. 10.1002/ajh.24210
- By:
- Publication type:
- Article
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 9, p. 755, doi. 10.1002/ajh.24034
- By:
- Publication type:
- Article
How I treat newly diagnosed chronic myeloid leukemia in 2015.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 2, p. 156, doi. 10.1002/ajh.23887
- By:
- Publication type:
- Article
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 10, p. 947, doi. 10.1002/ajh.23788
- By:
- Publication type:
- Article
First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 10, p. E184, doi. 10.1002/ajh.23804
- By:
- Publication type:
- Article
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 7, p. 732, doi. 10.1002/ajh.23728
- By:
- Publication type:
- Article
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 11, p. E125, doi. 10.1002/ajh.23338
- By:
- Publication type:
- Article
Chronic myeloid leukemia 2011: Successes, challenges, and strategies-Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 9, p. 811, doi. 10.1002/ajh.22097
- By:
- Publication type:
- Article
Choosing the right TKI for chronic myeloid leukemia: When the truth lies in 'long-term' safety and efficacy.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 7, p. 531, doi. 10.1002/ajh.22084
- By:
- Publication type:
- Article
miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-65404-7
- By:
- Publication type:
- Article
Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma.
- Published in:
- Cancers, 2021, v. 13, n. 17, p. 4422, doi. 10.3390/cancers13174422
- By:
- Publication type:
- Article
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling.
- Published in:
- Cancers, 2018, v. 10, n. 12, p. 509, doi. 10.3390/cancers10120509
- By:
- Publication type:
- Article
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.
- Published in:
- Cancers, 2018, v. 10, n. 3, p. 62, doi. 10.3390/cancers10030062
- By:
- Publication type:
- Article
Differential lysis of melanoma clones by autologous recombinant interleukin 2-activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx).
- Published in:
- International Journal of Cancer, 1988, v. 42, n. 4, p. 544, doi. 10.1002/ijc.2910420412
- By:
- Publication type:
- Article
In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2.
- Published in:
- International Journal of Cancer, 1988, v. 41, n. 5, p. 700, doi. 10.1002/ijc.2910410511
- By:
- Publication type:
- Article
Procoagulant activity of mouse and human cultured cells following various types of transformation.
- Published in:
- International Journal of Cancer, 1985, v. 35, n. 3, p. 411, doi. 10.1002/ijc.2910350318
- By:
- Publication type:
- Article
Cardiac, Vascular and Hypertension Safety of Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S294, doi. 10.1016/j.clml.2019.07.243
- By:
- Publication type:
- Article
Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S290, doi. 10.1016/j.clml.2019.07.235
- By:
- Publication type:
- Article
An Observational Study of Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) After 1, 3, and 5 Years of Tyrosine Kinase Inhibitor (TKI) Therapy (SIMPLICITY).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S229, doi. 10.1016/j.clml.2018.07.105
- By:
- Publication type:
- Article
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Bosutinib (BOS) vs Imatinib (IM) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results from the BFORE Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S316, doi. 10.1016/j.clml.2017.07.117
- By:
- Publication type:
- Article
Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV.
- Published in:
- Journal of Oncology, 2010, p. 1, doi. 10.1155/2010/530130
- By:
- Publication type:
- Article
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia.
- Published in:
- Journal of Cellular & Molecular Medicine, 2023, v. 27, n. 20, p. 3053, doi. 10.1111/jcmm.17868
- By:
- Publication type:
- Article
Bcr-Abl stabilizes β-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
- Published in:
- EMBO Journal, 2007, v. 26, n. 5, p. 1456, doi. 10.1038/sj.emboj.7601485
- By:
- Publication type:
- Article
Imbalanced Angiogenesis in Pregnancies Complicated by SARS-CoV-2 Infection.
- Published in:
- Viruses (1999-4915), 2022, v. 14, n. 10, p. N.PAG, doi. 10.3390/v14102207
- By:
- Publication type:
- Article
Letter to the Editor: SFlt-1 and PlGF Levels in Pregnancies Complicated by SARS-CoV-2 Infection.
- Published in:
- Viruses (1999-4915), 2021, v. 13, n. 12, p. 2377, doi. 10.3390/v13122377
- By:
- Publication type:
- Article
Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 6, p. 808, doi. 10.1111/ejh.13608
- By:
- Publication type:
- Article
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic‐phase CML in clinical practice: 3‐year European SIMPLICITY data.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 1, p. 82, doi. 10.1111/ejh.13524
- By:
- Publication type:
- Article
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase--Positive Lymphoma Patients.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 2, p. 1, doi. 10.1093/jnci/djt378
- By:
- Publication type:
- Article
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 7, p. 553, doi. 10.1093/jnci/djr060
- By:
- Publication type:
- Article
Development of c-Kit-expressing Small-Cell Lung Cancer in Chronic Myeloid Leukemia Patient During Imatinib Treatment.
- Published in:
- 2004
- By:
- Publication type:
- Letter
The Prognosis for Patients With Chronic Myeloid Leukemia Who Have Clonal Cytogenetic Abnormalities in Philadelphia Chromosome-Negative Cells.
- Published in:
- Cancer (0008543X), 2007, v. 110, n. 7, p. 1509, doi. 10.1002/cncr.22936
- By:
- Publication type:
- Article
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
- Published in:
- Transfusion, 2005, v. 45, n. 7, p. 1214, doi. 10.1111/j.1537-2995.2005.00175.x
- By:
- Publication type:
- Article
Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2014, v. 4, p. 69, doi. 10.2147/BLCTT.S35349
- By:
- Publication type:
- Article